These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26399382)

  • 1. Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
    Jung YS; Kim M; Lee JH; Kim DW; Park HJ
    Br J Dermatol; 2016 Feb; 174(2):456-8. PubMed ID: 26399382
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Schiffer CA
    N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
    [No Abstract]   [Full Text] [Related]  

  • 3. The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
    Togasaki-Yoshimoto E; Shono K; Onoda M; Yokota A
    Leuk Lymphoma; 2014 Feb; 55(2):453-6. PubMed ID: 23697842
    [No Abstract]   [Full Text] [Related]  

  • 4. Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.
    Gallipoli P; Shepherd P; Irvine D; Drummond M; Holyoake T
    Br J Haematol; 2011 Oct; 155(1):128-30. PubMed ID: 21517814
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic myeloid leukemia: advances in diagnosis and management.
    Noronha S; Sawyer S
    JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
    [No Abstract]   [Full Text] [Related]  

  • 6. High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.
    Martz J; Jain S; Vahdat LT; Qin L; Mosquera JM; Antonescu CR; Popa EC
    J Clin Oncol; 2013 Apr; 31(11):e181-5. PubMed ID: 23439757
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Defuentes G; Bladé JS; Berets O
    N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral BMS-354825 rescues Gleevec-resistant CML.
    Cancer Biol Ther; 2004 Aug; 3(8):700. PubMed ID: 15751154
    [No Abstract]   [Full Text] [Related]  

  • 11. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Quintás-Cardama A; Cortés JE; Kantarjian H
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S82-8. PubMed ID: 19254885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
    Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
    Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
    Novitzky-Basso I; Craddock C
    Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
    [No Abstract]   [Full Text] [Related]  

  • 15. [Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
    Saito M; Izumiyama K; Mori A; Irie T; Tanaka M; Morioka M; Saga A; Musashi M; Kato T; Meguro T; Tanino M
    Rinsho Ketsueki; 2014 Jan; 55(1):130-2. PubMed ID: 24492046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
    Karakulak UN; Aladag E; Hekimsoy V; Sahiner ML; Kaya EB; Ozer N; Aksu S; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Sayinalp N; Haznedaroglu IC
    Cardiovasc Toxicol; 2021 Mar; 21(3):216-223. PubMed ID: 33068232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.
    Larson JS; Bergstrom LK; Cameron JD; Erickson LA; Grimm TE
    Arch Ophthalmol; 2007 Jul; 125(7):985-6. PubMed ID: 17620589
    [No Abstract]   [Full Text] [Related]  

  • 18. Facial acneiform rash associated with sorafenib.
    Fleta-Asín B; Vañó-Galván S; Ledo-Rodríguez A; Truchuelo-Díez M; Jaén-Olasolo P
    Dermatol Online J; 2009 Apr; 15(4):7. PubMed ID: 19450400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
    Kantarjian H
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.